Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 28:bjophthalmol-2018-311923.
doi: 10.1136/bjophthalmol-2018-311923. Online ahead of print.

Prior non-irradiative focal therapies do not compromise the efficacy of delayed episcleral plaque brachytherapy in retinoblastoma

John T Lucas  1 , Rose McGee  2 , Catherine A Billups  3 , Ibrahim Qaddoumi  2 , Thomas E Merchant  4 , Rachel C Brennan  2   5   6 , Jiangrong Wu  3 , Matthew W Wilson  2   5   7
Affiliations

Prior non-irradiative focal therapies do not compromise the efficacy of delayed episcleral plaque brachytherapy in retinoblastoma

John T Lucas et al. Br J Ophthalmol. .

Abstract

Background/aims: Non-irradiative local therapies have shown promise in delaying or supplanting external beam radiotherapy (EBRT) and enucleation in patients with retinoblastoma. We hypothesised that prior focal therapy does not compromise the efficacy of delayed episcleral plaque brachytherapy (epBRT).

Methods: We performed an institutional review board-approved medical record review of patients with retinoblastoma who were treated with I-125 epBRT prior to (primary) or following chemoreduction (delayed), alone and in combination with non-irradiative focal therapy. Clinical and treatment characteristics were retrieved. Treatment failure was defined as the need for subsequent EBRT and/or enucleation. Event-free and ocular survival rates were calculated from the date of plaque placement. The cumulative incidences (CIs) of treatment failure and enucleation were compared across strata using Gray's test.

Results: We identified 50 patients with retinoblastoma (54 eyes), who received a total of 56 plaques between January 1986 and December 2010, with a median follow-up of 8.3 years (range, 0.8-21.2 years). The median time from diagnosis to plaque placement was 12.7 months (range, 0.1-128 months). The CI and 95% CI of treatment failure and enucleation following epBRT at 5 years was 37%±7.2% and42.2%±7.3%, respectively. The lack of prior diode or green laser therapy was predictive of increased risk for treatment failure (p=0.02 and 0.03). International Classification group C or D was predictive of decreased time to enucleation (p=0.004). The use of any focal therapy was not predictive of time to treatment failure (p=0.33).

Conclusions: The use of non-irradiative focal therapies prior to or following epBRT does not decrease the time to enucleation or treatment failure.

Keywords: clinical trial; treatment medical; treatment other; treatment surgery; vision.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

FIGURE 1:
FIGURE 1:
A) Overall cumulative incidence of treatment failure and enucleation. B) Cumulative incidence of enucleation for eyes treated with brachytherapy by International Classification group.
See this image and copyright information in PMC

References

    1. Aerts I, Pacquement H, Doz F, et al. Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer 2004;40(10):1522–9 doi: 10.1016/j.ejca.2004.03.023[published Online First: Epub Date]|. - DOI - PubMed
    1. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85(14):1121–8 - PubMed
    1. Shields CL, Shields JA, De Potter P, et al. Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment. Ophthalmology 1993;100(2):216–24 - PubMed
    1. Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 2007;114(1):162–9 doi: 10.1016/j.ophtha.2006.06.042[published Online First: Epub Date]|. - DOI - PubMed
    1. American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address pec, Committee AO. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014;13(1):1–14 doi: 10.1016/j.brachy.2013.11.008[published Online First: Epub Date]|. - DOI - PubMed

LinkOut - more resources